Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tailored Ion Release of Polycaprolactone and Calcium Silicate Composite Fibers Attenuates Neutrophil Extracellular Trap Formation for Dentin-Pulp Complex Regeneration.

Biomaterials research·2026

Same author

Frequent Sweetened Beverage Consumption Is Associated With Accelerated Biological Aging: Evidence From a Population-Based Study and Gut Microbiota Analysis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Dopamine-driven mitochondrial reverse electron transport in immune cells mediates gut-brain ROS signaling during sleep deprivation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026

Same author

Associations of dietary diversity with type 2 diabetes in two Chinese cohorts: a multi-omics study.

Food & function·2026

Same author

ROS-Responsive Nanobubbles for Dual-Enhanced Ultrasound and Magnetic Resonance Imaging of Tumor Oxidative Stress.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex.

Vaishali Bagalkot¹, In-Hyun Lee, Mi Kyung Yu

¹Department of Life Science, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.

Molecular Pharmaceutics

|April 3, 2009

Summary

This study introduces a novel chemoimmunotherapy vehicle combining doxorubicin with plasmid DNA. This complex demonstrated improved drug delivery, reduced toxicity, and enhanced anti-tumor efficacy in preclinical models.

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Experiment Videos

Last Updated: Jun 24, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Area of Science:

Biomedical Engineering
Cancer Therapy
Drug Delivery Systems

Background:

Chemotherapy often faces challenges with drug delivery, toxicity, and efficacy.
Immunotherapy offers a complementary approach to cancer treatment.
Combining chemotherapy and immunotherapy presents a promising strategy for enhanced cancer treatment.

Purpose of the Study:

To develop and evaluate a novel chemoimmunotherapy vehicle.
To assess the efficacy and pharmacokinetics of a doxorubicin-plasmid complex.
To investigate the immunomodulatory effects and toxicity profile of the complex.

Main Methods:

Formation of a stable doxorubicin-plasmid complex via intercalation.
Pharmacokinetic studies in mice to compare complex vs. free doxorubicin clearance.
In vivo efficacy studies in NCI-H358 xenograft and 4T1 murine allograft models.
Assessment of systemic toxicity and cardiotoxicity through body weight monitoring and heart histology.
Analysis of cytokine levels (IL-12, IL-6, IFN-gamma) in serum and tumor tissues.

Main Results:

The doxorubicin-plasmid complex exhibited significantly slower plasma clearance compared to free doxorubicin.
The complex demonstrated comparable or superior tumor growth inhibition at lower doses in both xenograft and allograft models.
No severe systemic toxicity or cardiotoxicity was observed with the complex, unlike free doxorubicin.
Intravenous injection of the complex led to elevated levels of key cytokines (IL-12, IL-6, IFN-gamma).

Conclusions:

The developed doxorubicin-plasmid complex serves as an effective chemoimmunotherapy agent.
This approach improves drug pharmacokinetics, reduces toxicity, and enhances the immune response.
The combined delivery system shows significant potential for treating diverse tumor types.